摘要
目的:了解我院调脂药的应用情况及趋势。方法:采用约定日剂量方法,对我院2009-2011年调脂药的销售金额、品种、用药频度等进行统计、分析。结果:3年来,调脂药销售金额逐年上升,其中他汀类药占主导地位;从DDDs看,氟伐他汀(2011年为10.03万日)和阿托伐他汀(2011年为9.04万日)排序靠前,瑞舒伐他汀(2011年为4.24万日)迅速增长。结论:他汀类药占据我院调脂药市场的主要地位,在品种选择上体现了有效性、安全性和多样性等特点。
OBJECTIVE： To investigate the status quo and trend of lipid regulating agents used in our hospital. METHODS： The utilization of lipid regulating agents in our hospital during the period of 2009--2011 was analyzed statistically by the method of DDD in terms of consumption sum, kinds and DDDs, etc. RESULTS ： In the past 3 years, the consumption sum of lipid regulating agents increased year by year, in which the consumption sum of statin occupied the dominant position. In terms of DDDs, the utili- zation frequency of fluvastatin（100 300 days in 2011） and atorvastatin （90 400 days in 2011） took up top two places. That of rosu- vastatin （42 400 days in 2011） was increasing rapidly. CONCLUSION： Statins have occupied the main position in the market of lipid regulating agents in our hospital. The choice of drug variety is characterized by efficacy, safety and diversity, etc.
出处
《中国药房》
CAS
CSCD
2012年第42期3958-3960,共3页
China Pharmacy
关键词
调脂药
销售金额
利用分析
Lipid regulating agents
Consumption sum
Utilization analysis
